Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
基本信息
- 批准号:10675646
- 负责人:
- 金额:$ 10.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdrenal GlandsAlanineAlpha CellAmino AcidsArginineAutomobile DrivingAwarenessBiological AssayBiologyBlood GlucoseBrainCarbohydratesCarbonCatecholaminesCell CommunicationCell physiologyCellsClinicalCognitionComplexComplicationDangerousnessDiabetes MellitusDoseDropsEmergency SituationEmergency treatmentEnergy-Generating ResourcesEtiologyExposure toFoundationsFunctional disorderG-Protein-Coupled ReceptorsGastric Inhibitory PolypeptideGenerationsGlassGlucagonGlucoseHepaticHumanHydrocortisoneHypoglycemiaImpairmentIngestionInsulinInsulin-Dependent Diabetes MellitusLabelLifeMeasuresMetabolicMetabolismMethodsModelingMolecularMusNeuronsNon obesePathway interactionsPatientsPersonsPhysiologicalPhysiologyRecurrenceResearch PersonnelScheduleSerious Adverse EventStimulusStrenuous ExerciseStreptozocinSystemTechnical ExpertiseTestingTherapeuticVariantWineWorkcareercounterregulationdesigndiabeticeffective therapyeffectiveness evaluationgastric inhibitory polypeptide receptorglucose outputglycemic controlin vivoinsightinsulin secretionisletmouse modelnovelnovel strategiespreventresponseside effect
项目摘要
PROJECT SUMMARY
Hypoglycemia is a dangerous complication of exogenous insulin therapy in Type 1 Diabetes (T1D) that is treated
by exogenous glucagon secretion. However, the use of exogenous glucagon has its own side effects and can
be complicated to administer in an emergency situation. As an alternative, stimuli that lead to robust endogenous
glucagon secretion could be effective to counter severe hypoglycemia. Glucagon secretion can be stimulated by
amino acids, like alanine and arginine, as well as by glucose-dependent insulinotropic peptide (GIP).
Remarkably, we found that while alanine or GIP alone induce modest increases in glucagon secretion, the
combination of alanine and GIP synergistically increase glucagon secretion in both isolated mouse and human
islets, as well as mice in vivo. A better understanding of the physiology of this glucagon and the mechanism of
its release is needed to determine if stimulating endogenous glucagon can treat hypoglycemia in T1D. We
hypothesize that endogenous -cell stimuli, such as GIP + alanine, can counter insulin-induced hypoglycemia.
The aims of this project are designed to elucidate whether -cell stimuli can mitigate severe hypoglycemia, how
the effects of -cell stimulation are changed in T1D, and what is the mechanism that alanine stimulates the -
cell to secrete glucagon. Successful completion of this project will enhance our understanding of the -cell and
provide insight for the basis of therapeutics for hypoglycemia or insulin co-therapies. In addition, the aims will
broaden the Candidate’s technical expertise and develop conceptual understanding of -cell physiology that will
provide a foundation for a career as an independent investigator.
项目摘要
低血糖是1型糖尿病(T1D)中外源胰岛素治疗的危险并发症
通过外源胰高血糖素的分泌。但是,使用外源胰高血糖素有其自身的副作用,可以
在紧急情况下进行管理很复杂。作为替代方案,导致内源性强大的刺激
胰高血糖素的分泌可能有效抵抗严重的低血糖症。胰高血糖素的分泌可以被
氨基酸,例如丙氨酸和精氨酸,以及依赖葡萄糖的胰岛素胡椒(GIP)。
值得注意的是,我们发现,尽管丙氨酸或GIP单独诱导胰高血糖素分泌的适度增加,但
丙氨酸和GIP的结合在分离的小鼠和人类中协同增加胰高血糖素的分泌
胰岛以及体内小鼠。更好地理解这种胰高血糖素的生理学和机制
需要释放以确定刺激的内源性胰高血糖素是否可以治疗T1D中的低血糖症。我们
假设内源性细胞刺激(例如GIP +丙氨酸)可以抵抗胰岛素诱导的低血糖。
该项目的目的旨在阐明细胞刺激是否可以减轻严重的低血糖症,如何如何
t1d中细胞刺激的作用发生了变化,丙氨酸刺激-的机制是什么
细胞到秘密胶。成功完成该项目将增强我们对细胞的理解
提供有关低血糖或胰岛素共同治疗疗法的洞察力。此外,目标将
扩大候选人的技术专业知识,并对细胞生理的概念理解,这将
为作为独立调查员的职业奠定了基础。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
- DOI:10.1016/j.molmet.2022.101638
- 发表时间:2022-12
- 期刊:
- 影响因子:8.1
- 作者:Yang, Bin;Gelfanov, Vasily M.;El, Kimberley;Chen, Alex;Rohlfs, Rebecca;DuBois, Barent;Hansen, Ann Maria Kruse;Perez-Tilve, Diego;Knerr, Patrick J.;'Alessio, David;Campbell, Jonathan E.;Douros, Jonathan D.;Finan, Brian
- 通讯作者:Finan, Brian
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kimberley M El其他文献
Kimberley M El的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kimberley M El', 18)}}的其他基金
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
- 批准号:
10427574 - 财政年份:2022
- 资助金额:
$ 10.57万 - 项目类别:
相似国自然基金
小细胞肺癌脑、肾上腺等多器官转移的谱系可塑性机制与干预研究
- 批准号:82330087
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
STAT5促进肾上腺素生成介导髓系造血及肿瘤免疫抑制的机制研究
- 批准号:82372908
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
慢性压力刺激调控释放的肾上腺素影响TAMs极化促进结肠癌进展的机制研究
- 批准号:82303327
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
内皮β3肾上腺素能受体调控线粒体功能参与血管衰老的作用研究
- 批准号:82370408
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SARS-CoV-2刺突蛋白作为β肾上腺素受体配体介导心脏炎症和纤维化的机制研究
- 批准号:82300295
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
- 批准号:
10427574 - 财政年份:2022
- 资助金额:
$ 10.57万 - 项目类别:
GLUCOCORTICOID RECEPTOR POST-TRANSLATIONAL MODIFICATIONS IN INSULIN RESISTANCE
胰岛素抵抗中的糖皮质激素受体翻译后修饰
- 批准号:
9980364 - 财政年份:2016
- 资助金额:
$ 10.57万 - 项目类别:
GLUCOCORTICOID RECEPTOR POST-TRANSLATIONAL MODIFICATIONS IN INSULIN RESISTANCE
胰岛素抵抗中的糖皮质激素受体翻译后修饰
- 批准号:
9337435 - 财政年份:2016
- 资助金额:
$ 10.57万 - 项目类别: